These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32401624)

  • 21. Anti-cytokine antibodies for rheumatic diseases.
    Atzeni F; Sarzi-Puttini P
    Curr Opin Investig Drugs; 2009 Nov; 10(11):1204-11. PubMed ID: 19876788
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Rheumatology. TNF alpha-inhibitors: infection risks? Practical recommendations].
    Faucherre M; Pazar B; So A; Aubry-Rozier B
    Rev Med Suisse; 2011 Jan; 7(277):75-6, 78-9. PubMed ID: 21309182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety profile of biological therapies for treating rheumatoid arthritis.
    Cañete JD; Hernández MV; Sanmartí R
    Expert Opin Biol Ther; 2017 Sep; 17(9):1089-1103. PubMed ID: 28657381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases.
    Wendling D; Paccou J; Berthelot JM; Flipo RM; Guillaume-Czitrom S; Prati C; Dernis E; Direz G; Ferrazzi V; Ristori JM;
    Semin Arthritis Rheum; 2011 Dec; 41(3):503-10. PubMed ID: 21862108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biological therapy and neurological manifestations. What do we know?
    Tejera-Segura B; Ferraz-Amaro I
    Reumatol Clin; 2017; 13(2):102-106. PubMed ID: 27373584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of neoplasms in pediatric patients with rheumatic disease exposed to anti-tumor necrosis factor therapies: a single Centre retrospective study.
    Okihiro A; Hasija R; Fung L; Cameron B; Feldman BM; Laxer R; Schneider R; Silverman E; Spiegel L; Yeung RSM; Tse SML
    Pediatr Rheumatol Online J; 2018 Mar; 16(1):17. PubMed ID: 29540190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity of anti-tumour necrosis factor drugs in rheumatic diseases.
    Spinelli FR; Valesini G
    Clin Exp Rheumatol; 2013; 31(6):954-63. PubMed ID: 23981925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-α agents in rheumatic diseases; A systematic review and meta-analysis.
    Komaki Y; Yamada A; Komaki F; Kudaravalli P; Micic D; Ido A; Sakuraba A
    J Autoimmun; 2017 May; 79():4-16. PubMed ID: 28209290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TNF-alpha antagonism and cancer risk in rheumatoid arthritis: is continued vigilance warranted?
    Park HJ; Ranganathan P
    Discov Med; 2012 Mar; 13(70):229-34. PubMed ID: 22463799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of tuberculosis comparison in new users of antitumour necrosis factor-α and with existing disease-modifying antirheumatic drug therapy.
    Chan MJ; Wen YH; Huang YB; Chuang HY; Tain YL; Lily Wang YC; Hsu CN
    J Clin Pharm Ther; 2018 Apr; 43(2):256-264. PubMed ID: 29119581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor necrosis factor inhibitors and risk of peripheral neuropathy in patients with rheumatic diseases.
    Etminan M; Sodhi M; Samii A; Carleton BC; Kezouh A; Antonio Avina-Zubieta J
    Semin Arthritis Rheum; 2019 Jun; 48(6):1083-1086. PubMed ID: 30337056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum uric acid increases in patients with systemic autoimmune rheumatic diseases after 3 months of treatment with TNF inhibitors.
    Hasikova L; Pavlikova M; Hulejova H; Kozlik P; Kalikova K; Mahajan A; Herrmann M; Stiburkova B; Zavada J
    Rheumatol Int; 2019 Oct; 39(10):1749-1757. PubMed ID: 31363829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice.
    Cantini F; Niccoli L; Capone A; Petrone L; Goletti D
    Expert Opin Drug Saf; 2019 May; 18(5):415-425. PubMed ID: 31066297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relative risk of tuberculosis in patients with rheumatic diseases managed with anti-tumour necrosis factor-alpha therapy: A nationwide cohort study.
    Aydin V; Akici A; Isli F; Aksoy M; Aydin M; Gursoz H
    J Clin Pharm Ther; 2019 Aug; 44(4):553-560. PubMed ID: 30763469
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy.
    Lee YH; Bae SC; Song GG
    Clin Exp Rheumatol; 2013; 31(1):118-21. PubMed ID: 23111095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients.
    Salliot C; Gossec L; Ruyssen-Witrand A; Luc M; Duclos M; Guignard S; Dougados M
    Rheumatology (Oxford); 2007 Feb; 46(2):327-34. PubMed ID: 16880188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic and localized infection by Candida species in patients with rheumatic diseases receiving anti-TNF therapy.
    Aikawa NE; Rosa DT; Del Negro GM; Moraes JC; Ribeiro AC; Saad CG; Silva CA; Bonfá E
    Rev Bras Reumatol Engl Ed; 2016; 56(6):478-482. PubMed ID: 27914593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
    Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD
    Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001).
    Furst DE; Keystone EC; Breedveld FC; Kalden JR; Smolen JS; Antoni CE; Burmester GR; Crofford LJ; Kavanaugh A
    Ann Rheum Dis; 2001 Nov; 60 Suppl 3(Suppl 3):iii2-5. PubMed ID: 11890647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.